TARGETED PROTEOMIC ANALYSIS OF 14-3-3 SIGMA, A P53 EFFECTOR COMMONLY SILENCED I
TARGETED PROTEOMIC ANALYSIS OF 14-3-3 SIGMA, A P53 EFFECTOR COMMONLY SILENCED I
批准号:
7420736
负责人:
HEIKO HERMEKING
金额:
$0.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-20 至 2007-08-31
关键词:
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To comprehensively identify proteins interacting with 14-3-3 sigma in vivo, tandem affinity purification and the multidimensional protein identification technology were combined to characterize 117 proteins associated with 14-3-3 sigma in human cells. The majority of identified proteins contained one or several phosphorylatable 14-3-3-binding sites indicating a potential direct interaction with 14-3-3 sigma. 25 proteins were not previously assigned to any function and were named SIP2-26 (for 14-3-3 sigma-interacting protein). Among the 92 interactors with known function were a number of proteins previously implicated in oncogenic signaling (APC, A-RAF, B-RAF, and c-RAF) and cell cycle regulation (AJUBA, c-TAK, PTOV-1, and WEE1). The largest functional classes comprised proteins involved in the regulation of cytoskeletal dynamics, polarity, adhesion, mitogenic signaling, and motility. Accordingly ectopic 14-3-3 sigma expression prevented cellular migration in a wounding assay and enhanced mitogen-activated protein kinase signaling. The functional diversity of the identified proteins indicates that induction of 14-3-3 sigma could allow p53 to affect numerous processes in addition to the previously characterized inhibitory effect on G2/M progression. The data suggest that the cancer-specific loss of 14-3-3 sigma expression by epigenetic silencing or p53 mutations contributes to cancer formation by multiple routes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
LARGE-SCALE IDENTIFICATION OF C-MYC-ASSOCIATED PROTEINS
-
批准号:7602154
-
项目类别:
-
资助金额:$0.62万
-
财政年份:2007
-
负责人:HEIKO HERMEKING
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于SERS纳米标签和光子晶体的单细胞Western Blot定量分析技术研究
-
批准号:31900571
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:刘兵
-
依托单位:
研究蝙蝠冬眠現象的分子进化机制
-
批准号:31100273
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:潘逸萱
-
依托单位:
消化道环境胁迫对双歧杆菌黏附作用的影响及该菌胁迫应答的表征
-
批准号:31171719
-
项目类别:面上项目
-
资助金额:65.0万元
-
批准年份:2011
-
负责人:孟祥晨
-
依托单位:
沙眼衣原体pORF5蛋白功能及其与宿主细胞相互作用的研究
-
批准号:30970165
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2009
-
负责人:李忠玉
-
依托单位:
高通量组蛋白翻译后修饰分析技术的建立及其在表观遗传学研究中的应用
-
批准号:90919047
-
项目类别:重大研究计划
-
资助金额:60.0万元
-
批准年份:2009
-
负责人:杨福全
-
依托单位:
转录调控中起作用的细胞周期激酶的鉴定及其作用机制研究
-
批准号:30970625
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2009
-
负责人:李沁桐
-
依托单位:
口服MHC肽诱导的受体Treg源性exosome干预肾移植排斥反应的机制研究
-
批准号:30872580
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2008
-
负责人:黄赤兵
-
依托单位:
食源性肥胖大鼠下丘脑摄食相关蛋白的筛选及功能研究
-
批准号:30870791
-
项目类别:面上项目
-
资助金额:28.0万元
-
批准年份:2008
-
负责人:田德润
-
依托单位:
比较分析IgA肾病中医主要证型肾系膜细胞的蛋白质组学
-
批准号:30672576
-
项目类别:面上项目
-
资助金额:27.0万元
-
批准年份:2006
-
负责人:李顺民
-
依托单位:
蛋白质组学指纹图谱技术差异蛋白放射性核素肿瘤显像
-
批准号:30570523
-
项目类别:面上项目
-
资助金额:26.0万元
-
批准年份:2005
-
负责人:李少林
-
依托单位: